Anupam Rasayan India Ltd announced the submission of the transcript from their Q1 FY25 earnings call, highlighting a 15% and 10% revenue contribution from their Pharma and Polymer segments respectively, reflecting a shift towards a balanced portfolio for sustainable growth.